IMR Press / EJGO / Special Issues / 1627467880646

Pathogenesis, Diagnosis and Treatment of Gynaecological Tumors

Submission deadline: 31 January 2022
Special Issue Editors
Zhe-Sheng (Jason) Chen, MD, PhD
College of Pharmacy and Health Sciences, St. John's University, 8000 Utopia Parkway, Queens, New York, NY, USA
Interests: Cancer pharmacology; Drug discovery; Multidrug resistance (MDR)
Special Issue and Collections in IMR journals
Zhong-qiu Lin, MD, PhD
Obstetrics and Gynecology Memorial Hospital of Sun Yat-sen Sun Yat-sen University 107 Yan-jian West Road, Guangzhou510120, Guangdong, China
Interests: Cervical Cancer; Ovarian Cancer; Endometrial Cancer; Vulvar Cancer
Special Issue Information

Dear Colleagues,

Gynecological tumors are solid tumors happened in the reproductive system of women, including ovarian, cervical cancer, endometrial cancer and others.  These cancers seriously affect the health of women worldwide, and contributing considerably to the global cancer burden. Many conventional anticancer drugs have been used for gynaecological tumors.  For example, cisplatin, paclitaxel, methotrexate, vinorelbine and gemcitabine are often used for the treatment of gynaecological tumors.  However, they may lack therapeutic effects or cause cytotoxic effects. In addition, there are many reports of gynaecological cancer progression and recurrence due to cancer cells that resist to treatments.  
Significant progress has been made in the treatment of gynecological tumors in recent years. Molecular targeted therapies have emerged as clinically useful drugs for the cure of gynaecological tumors. Molecular mechanisms of carcinogenesis and recurrence of gynecological cancers are gaining better understanding due to recent advances in molecular biology and genomic research. However, there remains a need to uncover biomarkers for prognosis and predictive diagnosis, progression and recurrence of gynecological tumors, and challenges for new therapeutics remain.
In this topic, we welcome articles for the molecular and cellular biology, biomarkers, diagnostics, and the treatment of gynaecological tumors including conventional chemotherapy, small molecular targeted drugs and monoclonal antibodies for targeted therapy.  In addition, new technologies such as liquid biopsy, mRNA vaccines and gemonic editing therapy focused on gynecological tumors are also welcome.

Prof. Zhe-Sheng (Jason) Chen and Prof. Zhong-qiu Lin

Guest Editors

Cervical Cancer
Ovarian Cancer
Endometrial Cancer
Targeted Therapy
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1500 USD. Submitted papers should be well formatted and use good English.

Back to top